Acarix Beheer

Beheer criteriumcontroles 0/4

De CEO Acarix is Aamir Mahmood, benoemd in Feb2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde SEK 1.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 2.5 jaar.

Belangrijke informatie

Aamir Mahmood

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

CEO

Aamir Mahmood (48 yo)

less than a year

Tenure

Mr. Aamir Mahmood serves as President and Chief Executive Officer of Acarix AB (publ) since February 1, 2024. He serves as General Manager/Vice President Americas of MicroPort CRM. He has experience in cor...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Aamir Mahmood	President & Chief Executive Officer	less than a year	geen gegevens	0.30% SEK 1.2m
Claus Bo Christensen	Founder and Interim Head of R&D	no data	geen gegevens	0.019% SEK 74.0k
Christian Lindholm	CFO & Executive VP	8.8yrs	SEK 2.28m	0.0076% SEK 29.7k
Thomas Borch	Interim Chief Operating Officer	less than a year	geen gegevens	0.0042% SEK 16.3k
Jennifer Matson	Head of Medical Affairs	2.8yrs	geen gegevens	geen gegevens
Carma Connely	Head of Market Access & Customer Excellence	2.8yrs	geen gegevens	geen gegevens
Jeff Thomas	Head of US Sales	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ACARIX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Siberg	Independent Chairman of the Board	3.5yrs	SEK 526.00k	0.038% SEK 148.0k
Fredrik Buch	Independent Director	3.5yrs	SEK 263.00k	0.11% SEK 430.1k
Louise Janssen-Counotte	Independent Director	4.5yrs	SEK 263.00k	geen gegevens
Ulf Rosén	Independent Director	10.8yrs	SEK 220.00k	0.94% SEK 3.7m
David Erlinge	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Morten Bottcher	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Peter Clemmensen	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
John Cleland	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Mikael Thorén	Independent Director	1.5yrs	SEK 154.00k	2.97% SEK 11.7m
Deepak Talreja	Medical Advisor	1.3yrs	geen gegevens	geen gegevens
Saumil Oza	Member of the Advisory Board	less than a year	geen gegevens	geen gegevens
Dave Braun	Member of the Advisory Board	less than a year	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ACARIX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Acarix Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

Acarix AB (publ) Approves Board Elections

High number of new and inexperienced directors

Acarix Appoints New Members to the Advisory Board

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Recent updates

New major risk - Share price stability

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)

Acarix Expands Within US Wellness Exam Market

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

New 90-day low: kr1.12

Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study

Acarix Receives US Market Approval for the CADScor System

New 90-day high: kr1.29

Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR

Third quarter 2020 earnings released: kr0.11 loss per share

Acarix AB (publ) to Report Q1, 2021 Results on May 11, 2021

New 90-day high: kr1.22

Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million.

New 90-day low - kr0.73

Acarix AB (publ) to Report Q4, 2020 Results on Feb 18, 2021

Earnings released